Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.